Tweet
ALEXANDER SEIFALIAN IS A PROFESSOR OF NANOTECHNOLOGY AND REGENERATIVE MEDICINE
https://connect.innovateuk.org/web/a.seifalian/summary
Alexander Marcus Seifalian is a Professor of Nanotechnology and
Regenerative Medicine, and director of Director of UCL Centre for
Nanotechnology & Regenerative Medicine at University College London
(UCL-CNRM).
He completed his education at University of London and University
College London Medical School. He is a Fellow of the Institute of
Nanotechnology (FIoN) and Fellow of Society of Biology (FSB), and
has published over 321 peer-reviewed research papers, 31 book chapter
contributions and 4 families of UK and International patents.
During his career he has led and managed many large projects with
multidisciplinary teams with very successful outcomes in terms
of commercialisation and translation to patients including: 1)
The development and commercialisation of a bypass graft for vascular
access for haemodialysis; 2) The development of bioreactors with fluid
dynamic systems; 3) Derived non-invasive techniques to monitor shear
stress in vivo as well as on cells in a physiological flow circuit
using RF ultrasound signalling; 4) Techniques to extract RNA from
porous scaffolds; 5) Developed laser activated vascular sealants
that have been commercialised for vascular, liver and brain surgery,
and 6) As part of an EU grant, he worked on the development of a
miniature implantable portal blood pump. His role involved designing
the pump for biocompatibility and in vitro and in vivo evaluations. His
current projects have led to the development of cardiovascular implants
using nanomaterials and stem cell technology, and the development of
organs using tissue engineering and nanoparticles for detection and
treatment of cancer. He has also developed a family of nanomaterials
and nanocomposite polymers for a range of biomedical applications. He
was awarded the top prize in the field for development of nanomaterials
and technologies for cardiovascular implants in 2007 by Medical Future
Innovation, and in 2009 received a Business Innovation Award from
UK Trade & Investment (UKTI) in the Life Sciences and Healthcare
category. More recently (2011), he developed a lacrimal drainage
conduit, vascular bypass graft, and world first synthetic trachea
made from nanocomposite polymers and stem cells and delivered them
from the laboratory directly to human patients.
He has created a huge amount of media interest for his R&D efforts
including a first in man bypass graft, lacrimal duct, trachea and
many other medical devices, and has over 380 international media
reports cited worldwide.
From: Emil Lazarian | Ararat NewsPress
https://connect.innovateuk.org/web/a.seifalian/summary
Alexander Marcus Seifalian is a Professor of Nanotechnology and
Regenerative Medicine, and director of Director of UCL Centre for
Nanotechnology & Regenerative Medicine at University College London
(UCL-CNRM).
He completed his education at University of London and University
College London Medical School. He is a Fellow of the Institute of
Nanotechnology (FIoN) and Fellow of Society of Biology (FSB), and
has published over 321 peer-reviewed research papers, 31 book chapter
contributions and 4 families of UK and International patents.
During his career he has led and managed many large projects with
multidisciplinary teams with very successful outcomes in terms
of commercialisation and translation to patients including: 1)
The development and commercialisation of a bypass graft for vascular
access for haemodialysis; 2) The development of bioreactors with fluid
dynamic systems; 3) Derived non-invasive techniques to monitor shear
stress in vivo as well as on cells in a physiological flow circuit
using RF ultrasound signalling; 4) Techniques to extract RNA from
porous scaffolds; 5) Developed laser activated vascular sealants
that have been commercialised for vascular, liver and brain surgery,
and 6) As part of an EU grant, he worked on the development of a
miniature implantable portal blood pump. His role involved designing
the pump for biocompatibility and in vitro and in vivo evaluations. His
current projects have led to the development of cardiovascular implants
using nanomaterials and stem cell technology, and the development of
organs using tissue engineering and nanoparticles for detection and
treatment of cancer. He has also developed a family of nanomaterials
and nanocomposite polymers for a range of biomedical applications. He
was awarded the top prize in the field for development of nanomaterials
and technologies for cardiovascular implants in 2007 by Medical Future
Innovation, and in 2009 received a Business Innovation Award from
UK Trade & Investment (UKTI) in the Life Sciences and Healthcare
category. More recently (2011), he developed a lacrimal drainage
conduit, vascular bypass graft, and world first synthetic trachea
made from nanocomposite polymers and stem cells and delivered them
from the laboratory directly to human patients.
He has created a huge amount of media interest for his R&D efforts
including a first in man bypass graft, lacrimal duct, trachea and
many other medical devices, and has over 380 international media
reports cited worldwide.
From: Emil Lazarian | Ararat NewsPress